Clinical Trials
160 trials[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
Aalborg University Hospital
PANEL
University Hospital, Rouen
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
Peking Union Medical College Hospital
Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada
PeriPharm
TILsOV
Centre Oscar Lambret
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Mayo Clinic
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Herlev Hospital
AM-003
University of Virginia
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Roswell Park Cancer Institute
Exercise Preconditioning in Ovarian Cancer
University of Virginia
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Dana-Farber Cancer Institute
NIRAPK
Hospices Civils de Lyon
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
Mayo Clinic
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Thomas Jefferson University
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
University of Oklahoma
MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Pennsylvania
COMPASS
North Eastern German Society of Gynaecological Oncology
TOASTIT
Mayo Clinic
Newton
Mario Negri Institute for Pharmacological Research
REVOCAN
Gustave Roussy, Cancer Campus, Grand Paris
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures
University of California, Irvine
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
University of Pittsburgh
ECOvar
Stiftung Swiss Tumor Institute
Long Term Survivors in Ovarian Cancer
University Medical Center Groningen
Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact
Milton S. Hershey Medical Center
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
EXPERT
Ente Ospedaliero Ospedali Galliera
Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer
University of Washington
Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer
Shandong University
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
SCRI Development Innovations, LLC
The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors
University of Washington
BRCA
University of Alabama at Birmingham
BrUOG 390: Neoadjuvant Treatment With Talazoparib
Brown University
VIPIDO
Universitaire Ziekenhuizen KU Leuven
Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer
Ludwig Institute for Cancer Research
PSMA PET and MRI in Gynecological Cancers
University of Wisconsin, Madison
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
M.D. Anderson Cancer Center
Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study
Cantonal Hospital of St. Gallen
Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.
University Health Network, Toronto
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
OLIVIA
University Medical Center Groningen
Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients
University of Wisconsin, Madison
Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma
UConn Health